Created at	Source	Raw Value	Validated value
July 12, 2022, 1:30 a.m.	usa	Efficacy endpoint-1 (Phase II);Efficacy endpoint-2 (Phase II);Establishment of a CoV-2-STs bank;Establishment of a CoV-2-STs bank of broad HLA coverage;Pharmacodynamic endpoint-1 (Phase I);Pharmacodynamic endpoint-2 (Phase I and II);Pharmacodynamic endpoint-3 (Phase II);Safety endpoints (Phase I and II)	Efficacy endpoint-1 (Phase II);Efficacy endpoint-2 (Phase II);Establishment of a CoV-2-STs bank;Establishment of a CoV-2-STs bank of broad HLA coverage;Pharmacodynamic endpoint-1 (Phase I);Pharmacodynamic endpoint-2 (Phase I and II);Pharmacodynamic endpoint-3 (Phase II);Safety endpoints (Phase I and II)